Neuroendocrine Tumors

The FDA tentatively approved PNT2003, a radioequivalent to lutetium Lu 177 dotatate, for adults with GEP-NETs based on comparable efficacy and safety data.

Mauro Cives, MD, discussed "immune niches," neoantigen mapping, and strategies to minimize adverse effects in healthy tissue for this treatment modality.

Cytokines such as IL-17B, TNF-α, and IL-6 are essential in driving neuroendocrine differentiation and “reprogramming” healthy tissue.

Data from 2 trials at the 2024 and 2025 ASCO Annual Meetings demonstrate the PD-L1/4-1BB bispecific antibody’s efficacy and safety in this population.

Toxicities with streptozotocin/5-fluorouracil and everolimus were comparable with other orally available chemotherapeutic schemes in this NET population.

Data from a phase 1/2a trial show no dose-limiting toxicities associated with ELC-100 among patients with neuroendocrine tumors.

Results from the phase 3 COMPETE trial demonstrated that 177Lu-edotreotide improved PFS and ORR compared with everolimus in patients with GEP-NETs.

Micheal C. Soulen, MD, spoke about his presentation on the CapTemY90 trial at the 2025 NANETS Multidisciplinary NET Medical Symposium.

Considering historical trends of underpowered data in NET surgical studies, CUTNETs established a collaboration of surgical teams to better power research.

A manageable safety profile and survival benefit was observed across patient groups with somatostatin receptor–positive GEP-NETs.

Data from the phase 3 CABINET trial support the CHMP’s positive opinion of cabozantinib in well-differentiated extrapancreatic or pancreatic NETs.

Anna Greene, PhD, spoke about how this under-studied disease needs increased funding and more awareness.

Anna Greene, PhD, highlights the NETRF’s role as the largest funder of NET research, their current research funding opportunities, and its commitment to patient support.

Data from the phase 3 CABINET study support the approval of cabozantinib in patients with pancreatic and extra-pancreatic neuroendocrine tumors.

Phase 3 data show that ITM-11 produced favorable safety results among patients with gastroenteropancreatic neuroendocrine tumors.

A phase 2 trial revealed survival with ramucirumab plus somatostatin was consistent with other VEGF pathways in treating advanced neuroendocrine tumors.

Investigators are assessing treatment with ELC-100 among patients with pancreatic neuroendocrine tumors as part of a phase 1/2 trial.

Brett L. Ecker, MD, discusses the importance of multidisciplinary collaboration in improving patient outcomes in neuroendocrine tumors.

Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.

Panelists discuss how next-generation sequencing can identify actionable mutations and molecular alterations in neuroendocrine tumors, potentially guiding personalized treatment decisions and clinical trial eligibility while advancing our understanding of tumor biology.

Panelists discuss how treatment selection for well-differentiated grade 3 neuroendocrine tumors requires careful consideration of factors including Ki-67 index, tumor biology, and disease progression rate to determine whether platinum-based chemotherapy or targeted therapies are most appropriate.

Panelists discuss how somatostatin analogues, while effective in controlling hormone-related symptoms and tumor growth in neuroendocrine tumors, face challenges including drug resistance, optimal dosing strategies, and timing of initiation in the treatment sequence.

Panelists discuss how accurate grading and classification of neuroendocrine tumors is crucial for determining prognosis and treatment strategies, focusing on key histopathological features.

FDA acceptance is based on phase 3 CABINET trial results, with cabozantinib showing a PFS improvement in patients with pancreatic neuroendocrine tumors.

Data from 2 NETTER trials support lutetium Lu 177 dotatate's approval in somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.